Loading...
01/11 03:19
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings report indicates positive financial performance with revenue growth and improved margins, but there are concerns regarding liquidity constraints and profitability challenges. The Q&A session highlighted uncertainties in achieving target utilization levels and market expansion timelines. Despite a new CPT code and increased system installations, the dependency on routine users and economic uncertainties pose risks. The recent stock offering and restricted cash further temper optimism. Given these mixed signals, the stock price is expected to remain relatively stable over the next two weeks.
Total Revenue $7.4 million, reflecting an increase of 21% compared to the third quarter of 2024. Core revenues increased by 12% year-over-year in Q3 2025 after adjusting for a write-down of $0.5 million in revenues from discontinued clinical services in 2024. The increase is attributed to the focus on routine users and increased utilization.
Flow Cells Sold 8,390 flow cells, a 7% increase compared to the same period last year. This growth reflects increased utilization within the routine use customer group.
Non-GAAP Gross Margin 46%, significantly higher than the 26% reported for the third quarter of 2024. The improvement is due to cost reduction, improvements in product manufacturing costs, and higher volumes.
Non-GAAP Operating Expense $9.7 million, a 40% reduction compared to $16.1 million in the third quarter of 2024. This reduction is attributed to disciplined cost management.
Installed Systems Net increase of 3 systems to 384 for the installed base as of the end of the third quarter of 2025. Year-to-date, 23 new systems have been installed.
Cash, Cash Equivalents, and Securities $31.8 million, of which $10.3 million was subject to certain restrictions. A $10 million public offering of common stock in September bolstered the balance sheet.
Consumables and Software Revenue Sales grew 15% year-over-year in the third quarter and 10% year-over-year for the first 9 months of 2025. This growth is due to the shift in product mix towards consumables and software.
Optical Genome Mapping (OGM) systems: Focus on transforming pathology to a digital future with OGM systems, Ionic system for nucleic acid isolation, and VIA software. These solutions simplify workflows in cytogenetics and molecular pathology.
Consumables and software: Consumables and software sales grew 15% year-over-year in Q3 2025, representing 72% of the product mix. This shift aligns with the strategy to focus on routine users.
New software upgrades: Upgrades to VIA software and compute platforms are on track for full commercial release, aiming to improve analysis of OGM, microarray, and next-generation sequencing data.
Global interest in OGM: Strong presence at the ASHG Annual Meeting and growing interest in regions like Japan. Publications and studies highlight OGM's utility in new cancer types and workflows.
CPT code for OGM: A second Category I CPT code for OGM was established, with CMS pricing it at $1,263.53, higher than microarray codes. This supports routine use of OGM in oncology and clinical genetic research globally.
Revenue growth: Total revenue for Q3 2025 was $7.4 million, a 21% increase compared to Q3 2024. Core revenues increased by 12% year-over-year after adjusting for discontinued clinical services.
Gross margin improvement: Non-GAAP gross margin for Q3 2025 was 46%, up from 26% in Q3 2024, driven by cost reductions and improved manufacturing efficiencies.
Operating expense reduction: Non-GAAP operating expenses reduced by 40% year-over-year to $9.7 million in Q3 2025.
Focus on routine users: Shifted strategy to drive utilization within a subset of routine users, leading to increased consumables and software revenues.
Reimbursement and guidelines: Efforts to build support for OGM reimbursement and inclusion in medical society guidelines are ongoing, supported by growing publications and clinical research genomes.
Revenue growth dependency on routine users: The company's strategy heavily relies on a subset of routine users for revenue growth. This dependency could pose a risk if these users reduce their utilization or switch to competitors.
Cash flow and liquidity constraints: The company ended the quarter with $31.8 million in cash, of which $10.3 million is restricted. While a recent $10 million public offering extended the cash runway, liquidity constraints could arise if growth and cost-saving initiatives do not materialize as planned.
Profitability challenges: Despite improvements, the company is still working on achieving profitability and scalability. Non-GAAP operating expenses have been reduced, but further cost reductions and revenue growth are critical to sustain operations.
Regulatory and reimbursement hurdles: The company is working on building support for optical genome mapping reimbursement and inclusion in medical society guidelines. Delays or failures in achieving these milestones could hinder adoption and revenue growth.
Market competition and adoption barriers: The company faces competitive pressures and challenges in driving adoption of its optical genome mapping solutions, particularly in new regions and applications.
Product mix shift risks: The shift in product mix towards consumables and software, while beneficial for margins, could expose the company to risks if demand for these products declines.
Economic and market uncertainties: Broader economic conditions and market uncertainties could impact customer spending and adoption of the company's solutions.
Full Year 2025 Revenue Guidance: Reiterated at $26 million to $30 million.
Fourth Quarter 2025 Revenue Expectation: Expected to be in the range of $7.5 million to $7.9 million.
OGM System Installations: Expected to exceed the prior range of 20 to 25 systems, likely surpassing the high end of that.
Gross Margin Outlook: While continued margin expansion is expected over time, the levels seen in recent quarters (46% non-GAAP gross margin) are representative of near-term expectations.
Optical Genome Mapping (OGM) Reimbursement: Progress in obtaining reimbursement support, with a new CPT code priced at $1,263.53, paving the way for more routine use of OGM globally.
The selected topic was not discussed during the call.
The earnings report indicates positive financial performance with revenue growth and improved margins, but there are concerns regarding liquidity constraints and profitability challenges. The Q&A session highlighted uncertainties in achieving target utilization levels and market expansion timelines. Despite a new CPT code and increased system installations, the dependency on routine users and economic uncertainties pose risks. The recent stock offering and restricted cash further temper optimism. Given these mixed signals, the stock price is expected to remain relatively stable over the next two weeks.
The earnings call presents a mixed picture. Financial performance shows a revenue decline but improved margins and cost reductions. Product development highlights growth in flowcell utilization and software adoption. However, market competition and system returns pose risks. The Q&A reveals opportunities for software expansion and strategic partnerships but also highlights uncertainties in system returns and reimbursement pricing. Overall, the sentiment is neutral, reflecting balanced positive and negative factors without a clear catalyst for significant stock price movement.
The earnings call reveals mixed signals: improved gross margins and reduced operating expenses are positives, while a significant revenue decrease and lack of shareholder return plans are negatives. The Q&A highlights stable routine user metrics and limited supply chain exposure, but management's vague responses on margins and trade impacts suggest caution. The revenue guidance aligns with expectations, but the absence of new partnerships or share buybacks limits positive sentiment. Overall, the factors balance out, leading to a neutral stock price prediction.
The earnings call presents a mixed picture: strong cost management and improved margins are positive, but revenue decline and supply chain challenges pose concerns. The Q&A reveals stable customer base and cautious optimism, but management's vague responses on gross margin and tariffs suggest uncertainty. Without a share repurchase program and given the market conditions, the overall sentiment is neutral. The stock is likely to remain within a -2% to 2% range over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
